AnalyzeDirect Kentaro Hirade et al. Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy Cell Reports Medicine.
Publication Date
August 29, 2025
How Analyze was Used
“Tumor volume was evaluated by CT imaging twice weekly. CT imaging was performed…and tumor volume was evaluated by Analyze 12.0 software (AnalyzeDirect, Inc). For the efficacy study, tumors were randomized once the mean tumor volume reached approximately 20 mm3.”
Keywords
Lung cancer, CD47, KRAS mutation, Immune checkpoint inhibitor
Author Affiliation(s)
Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan
